Alexandra Gomez Arteaga, MD, discusses the rationale behind a retrospective study comparing Orca-T with posttransplant ...
As the clinical utility of ctDNA continues to be assessed, it is becoming a valuable tool for various cancer types, including ...
What do you envision for the role of ADCs in the future treatment of HER-negative and HER2-low metastatic breast cancer?
During a Case-Based Roundtable® event, Andrew Yee, MD, discussed the use of carfilzomib-based regimens compared with other ...
Mazyar Shadman, MD, MPH, describes his clinical approach to treating patients with high-risk CLL/SLL, including those with or without del(17p) or TP53 mutations.
Francis P. Worden, MD, discusses future plans to investigate combination therapies and other novel treatments in the thyroid ...
The FDA has accepted and granted priority review to tab-cel, a treatment for Epstein Barr virus-positive posttransplant ...
During a Case-Based Roundtable® event, James M. Rossetti, DO, discussed the role of risk scoring and stratification tools and ...
Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus ...
The FDA has granted 7MW3711 an orphan drug designation (ODD) for the treatment of small cell lung cancer (SCLC). 7MW3711 is a ...
Barbara O'Brien, MD, discusses the goals and results of a study investigating tucatinib, trastuzumab, and capecitabine for ...
The FDA has granted a rare pediatric disease designation to SLS009 for treating pediatric acute myeloid leukemia.